TRPV1 mediates cellular uptake of anandamide and thus promotes endothelial cell proliferation and network-formation

Biology Open

Volumn 3, Issue 12, 2014, Pages 1164-1172

  Hofmann, Nicole A ^a   Barth, Sonja ^a   Waldeck Weiermair, Markus ^a   Klec, Christiane ^a   Strunk, Dirk ^b   Malli, Roland ^a   Graier, Wolfgang F ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

AEA; Anandamide; Anandamide transport; Angiogenesis; ECFC; Endothelial colony forming cells; Network formation; Proliferation; Transient receptor potential vanilloid 1; TRPV1

Indexed keywords

EID: 84979243178     PISSN: None     EISSN: 20466390     Source Type: Journal    
DOI: 10.1242/bio.20149571     Document Type: Article

References (48)

1. Basbaum, A. I., Bautista, D. M., Scherrer, G. and Julius, D. (2009). Cellular and molecular mechanisms of pain. Cell 139, 267-284.
2. Björklund, E., Larsson, T. N., Jacobsson, S. O. and Fowler, C. J. (2014). Ketoconazole inhibits the cellular uptake of anandamide via inhibition of FAAH at pharmacologically relevant concentrations. PLoS ONE9, e87542.
3. Blumberg, P. M., Pearce, L. V. and Lee, J. (2011). TRPV1 activation is not an allor-none event: TRPV1 partial agonism/antagonism and its regulatory modulation. Curr. Top. Med. Chem. 11, 2151-2158.
4. Bohlen, C. J., Priel, A., Zhou, S., King, D., Siemens, J. and Julius, D. (2010). A bivalent tarantula toxin activates the capsaicin receptor, TRPV1, by targeting the outer pore domain. Cell 141, 834-845.
5. Brailoiu, G. C., Oprea, T. I., Zhao, P., Abood, M. E. and Brailoiu, E. (2011). Intracellular cannabinoid type 1 (CB1 ) receptors are activated by anandamide. J. Biol. Chem. 286, 29166-29174.
6. Cao, E., Liao, M., Cheng, Y. and Julius, D. (2013). TRPV1 structures in distinct conformations reveal activation mechanisms. Nature 504, 113-118.
7. Caterina, M. J., Schumacher, M. A., Tominaga, M., Rosen, T. A., Levine, J. D. and Julius, D. (1997). The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389, 816-824.
8. Costa, B., Siniscalco, D., Trovato, A. E., Comelli, F., Sotgiu, M. L., Colleoni, M., Maione, S., Rossi, F. and Giagnoni, G. (2006). AM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic pain. Br. J. Pharmacol. 148, 1022-1032.
9. De Petrocellis, L., Melck, D., Ueda, N., Maurelli, S., Kurahashi, Y., Yamamoto, S., Marino, G. and Di Marzo, V. (1997). Novel inhibitors of brain, neuronal, and basophilic anandamide amidohydrolase. Biochem. Biophys. Res. Commun. 231, 82-88.
10. De Petrocellis, L., Bisogno, T., Maccarrone, M., Davis, J. B., Finazzi-Agro, A. and Di Marzo, V. (2001). The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J. Biol. Chem. 276, 12856-12863.
11. den Boon, F. S., Chameau, P., Schaafsma-Zhao, Q., van Aken, W., Bari, M., Oddi, S., Kruse, C. G., Maccarrone, M., Wadman, W. J. and Werkman, T. R. (2012). Excitability of prefrontal cortical pyramidal neurons is modulated by activation of intracellular type-2 cannabinoid receptors. Proc. Natl. Acad. Sci. USA 109, 3534-3539.
12. Deutsch, D. G., Goligorsky, M. S., Schmid, P. C., Krebsbach, R. J., Schmid, H. H., Das, S. K., Dey, S. K., Arreaza, G., Thorup, C., Stefano, G. et al. (1997). Production and physiological actions of anandamide in the vasculature of the rat kidney. JCI 100, 1538-1546.
13. Devane, W. A., Hanus, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A. and Mechoulam, R. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-1949.
14. Fegley, D., Kathuria, S., Mercier, R., Li, C., Goutopoulos, A., Makriyannis, A. and Piomelli, D. (2004). Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc. Natl. Acad. Sci. USA 101, 8756-8761.
15. Folkman, J. (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1, 27-30.
16. Fowler, C. J. (2013). Transport of endocannabinoids across the plasma membrane and within the cell. FEBS J. 280, 1895-1904.
17. Galve-Roperh, I., Chiurchiù, V., Díaz-Alonso, J., Bari, M., Guzmán, M. and Maccarrone, M. (2013). Cannabinoid receptor signaling in progenitor/stem cell proliferation and differentiation. Prog. Lipid Res. 52, 633-650.
18. Gatley, S. J., Gifford, A. N., Volkow, N. D., Lan, R. and Makriyannis, A. (1996). 123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors. Eur. J. Pharmacol. 307, 331-338.
19. Glaser, S. T., Abumrad, N. A., Fatade, F., Kaczocha, M., Studholme, K. M. and Deutsch, D. G. (2003). Evidence against the presence of an anandamide transporter. Proc. Natl. Acad. Sci. USA 100, 4269-4274.
20. Guindon, J. and Hohmann, A. G. (2011). The endocannabinoid system and cancer: therapeutic implication. Br. J. Pharmacol. 163, 1447-1463.
21. Gunthorpe, M. J., Rami, H. K., Jerman, J. C., Smart, D., Gill, C. H., Soffin, E. M., Luis Hannan, S., Lappin, S. C., Egerton, J., Smith, G. D. et al. (2004). Identification and characterisation of SB-366791, a potent and selective vanilloid receptor (VR1/TRPV1) antagonist. Neuropharmacology 46, 133-149.
22. Hillard, C. J. and Campbell, W. B. (1997). Biochemistry and pharmacology of arachidonylethanolamide, a putative endogenous cannabinoid. J. Lipid Res. 38, 2383-2398.
23. Hofmann, N. A., Ortner, A., Jacamo, R. O., Reinisch, A., Schallmoser, K., Rohban, R., Etchart, N., Fruehwirth, M., Beham-Schmid, C., Andreeff, M. et al. (2012). Oxygen sensing mesenchymal progenitors promote neovasculogenesis in a humanized mouse model in vivo. PLoS ONE 7, e44468.
24. Högestätt, E. D., Jönsson, B. A., Ermund, A., Andersson, D. A., Björk, H., Alexander, J. P., Cravatt, B. F., Basbaum, A. I. and Zygmunt, P. M. (2005). Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system. J. Biol. Chem. 280, 31405-31412.
25. Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R. et al. (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharm. Rev. 54, 161-202.
26. Ingram, D. A., Mead, L. E., Moore, D. B., Woodard, W., Fenoglio, A. and Yoder, M. C. (2005). Vessel wall-derived endothelial cells rapidly proliferate because they contain a complete hierarchy of endothelial progenitor cells. Blood 105, 2783-2786.
27. Kargl, J., Brown, A. J., Andersen, L., Dorn, G., Schicho, R., Waldhoer, M. and Heinemann, A. (2013). A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function. J. Pharmacol. Exp. Ther. 346, 54-66.
28. Liao, M., Cao, E., Julius, D. and Cheng, Y. (2013). Structure of the TRPV1 ion channel determined by electron cryo-microscopy. Nature 504, 107-112.
29. Ligresti, A., De Petrocellis, L., Hernán Pérez de la Ossa, D., Aberturas, R., Cristino, L., Moriello, A. S., Finizio, A., Gil, M. E., Torres, A. I., Molpeceres, J. et al. (2010). Exploiting nanotechnologies and TRPV1 channels to investigate the putative anandamide membrane transporter. PLoS ONE 5, e10239.
30. Maccarrone, M. (2013). Endocannabinoid signaling in cancer: a rather complex puzzle. Trends Pharmacol. Sci. 34, 426-427.
31. Martin, B. R., Beletskaya, I., Patrick, G., Jefferson, R., Winckler, R., Deutsch, D. G., Di Marzo, V., Dasse, O., Mahadevan, A. and Razdan, R. K. (2000). Cannabinoid properties of methylfluorophosphonate analogs. J. Pharmacol. Exp. Ther. 294, 1209-1218.
32. McFarland, M. J. and Barker, E. L. (2004). Anandamide transport. Pharmacol. Ther. 104, 117-135.
33. Min, J. K., Han, K. Y., Kim, E. C., Kim, Y. M., Lee, S. W., Kim, O. H., Kim, K. W., Gho, Y. S. and Kwon, Y. G. (2004). Capsaicin inhibits in vitro and in vivo angiogenesis. Cancer Res. 64, 644-651.
34. Muthian, S., Nithipatikom, K., Campbell, W. B. and Hillard, C. J. (2000). Synthesis and characterization of a fluorescent substrate for the N-arachidonoylethanolamine (anandamide) transmembrane carrier. J. Pharmacol. Exp. Ther. 293, 289-295.
35. Opitz, C. A., Rimmerman, N., Zhang, Y., Mead, L. E., Yoder, M. C., Ingram, D. A., Walker, J. M. and Rehman, J. (2007). Production of the endocannabinoids anandamide and 2-arachidonoylglycerol by endothelial progenitor cells. FEBS Lett. 581, 4927-4931.
36. Pertwee, R. G., Howlett, A. C., Abood, M. E., Alexander, S. P., Di Marzo, V., Elphick, M. R., Greasley, P. J., Hansen, H. S., Kunos, G., Mackie, K. et al. (2010). International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2 . Pharm. Rev. 62, 588-631.
37. Petersen, G., Moesgaard, B., Schmid, P. C., Schmid, H. H., Broholm, H., Kosteljanetz, M. and Hansen, H. S. (2005). Endocannabinoid metabolism in human glioblastomas and meningiomas compared to human non-tumour brain tissue. J. Neurochem. 93, 299-309.
38. Pisanti, S., Borselli, C., Oliviero, O., Laezza, C., Gazzerro, P. and Bifulco, M. (2007). Antiangiogenic activity of the endocannabinoid anandamide: correlation to its tumor-suppressor efficacy. J. Cell. Physiol. 211, 495-503.
39. Pisanti, S., Picardi, P., Prota, L., Proto, M. C., Laezza, C., McGuire, P. G., Morbidelli, L., Gazzerro, P., Ziche, M., Das, A. et al. (2011). Genetic and pharmacologic inactivation of cannabinoid CB1 receptor inhibits angiogenesis. Blood 117, 5541-5550.
40. Ralevic, V., Kendall, D. A., Jerman, J. C., Middlemiss, D. N. and Smart, D. (2001). Cannabinoid activation of recombinant and endogenous vanilloid receptors. Eur. J. Pharmacol. 424, 211-219.
41. Reinisch, A., Hofmann, N. A., Obenauf, A. C., Kashofer, K., Rohde, E., Schallmoser, K., Flicker, K., Lanzer, G., Linkesch, W., Speicher, M. R. et al. (2009). Humanized large-scale expanded endothelial colony-forming cells function in vitro and in vivo. Blood 113, 6716-6725.
42. Rinaldi-Carmona, M., Barth, F., Millan, J., Derocq, J. M., Casellas, P., Congy, C., Oustric, D., Sarran, M., Bouaboula, M., Calandra, B. et al. (1998). SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 284, 644-650.
43. Rozenfeld, R. and Devi, L. A. (2008). Regulation of CB1 cannabinoid receptor trafficking by the adaptor protein AP-3. FASEB J. 22, 2311-2322.
44. Starowicz, K., Nigam, S. and Di Marzo, V. (2007). Biochemistry and pharmacology of endovanilloids. Pharmacol. Ther. 114, 13-33.
45. van der Stelt, M., Trevisani, M., Vellani, V., De Petrocellis, L., Schiano Moriello, A., Campi, B., McNaughton, P., Geppetti, P. and Di Marzo, V. (2005). Anandamide acts as an intracellular messenger amplifying Ca2+ influx via TRPV1 channels. EMBO J. 24, 3026-3037.
46. Wagner, J. A., Varga, K., Ellis, E. F., Rzigalinski, B. A., Martin, B. R. and Kunos, G. (1997). Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature 390, 518-521.
47. Waldeck-Weiermair, M., Zoratti, C., Osibow, K., Balenga, N., Goessnitzer, E., Waldhoer, M., Malli, R. and Graier, W. F. (2008). Integrin clustering enables anandamide-induced Ca2+ signaling in endothelial cells via GPR55 by protection against CB1-receptor-triggered repression. J. Cell Sci. 121, 1704-1717.
48. Yoder, M. C., Mead, L. E., Prater, D., Krier, T. R., Mroueh, K. N., Li, F., Krasich, R., Temm, C. J., Prchal, J. T. and Ingram, D. A. (2007). Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 109, 1801-1809.